The panTB-HM Study Annual General Meeting (AGM) brought together partners, researchers, and site teams to reflect on five years of impactful collaboration to End TB. The sessions focused on progress, coordination, and shared learning across study sites and partner institutions.
The meeting opened with a comprehensive protocol overview by Principal Investigator Prof. Robert S. Wallis, who set the tone for a day centred on scientific integrity and partnership. Updates followed from participating sites — NIMR, TASK Eden, Clinical HIV Research Unit (Durban and Johannesburg), Instituto Nacional de Saúde (INS), and Aurum’s teams in Klerksdorp, Rustenburg, and Tembisa, each sharing operational highlights, recruitment progress, and insights from on-the-ground implementation.
The AGM showcased the study’s breadth of collaboration, featuring:
- A safety and efficacy briefing on sutezolid from TB Alliance
- A resistance overview on bedaquiline from Ludwig-Maximilians-Universität München
- A pharmacokinetics update from Radboudumc
- Blinded treatment arm results presented by The Aurum Institute
- Reflections on the GATES panTB trial from the Gates Medical Research Institute
These sessions underscored the study’s collective commitment to data quality, participant safety, and collaborative problem-solving, ending the day with open discussions on next steps and upcoming publications.
Reflecting on the study’s journey, Prof. Wallis highlighted its long-term significance:
“This project has been running for five years and has been successful overall. The study has gathered the perfect selection of TB patients. These findings will be highly relevant in many years to come.”
The panTB-HM study aims to evaluate a host-microbe targeted regimen that could meet WHO criteria for a pan-TB indication. By integrating host-directed therapy and focusing on long-term outcomes such as lung function and life expectancy, the study seeks to generate evidence that can shape future TB treatment policy.
This research is part of the European & Developing Countries Clinical Trials Partnership (EDCTP), supported by the European Union.
The consortium continues to advance the science of TB treatment, driven by innovation, collaboration, and a shared goal to EndTB.